This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saad, D. Articles by Spinale, F. G. Search for Related Content PubMed PubMed Citation Articles by Saad, D. Articles by Spinale, F. G.

The effects of endothelin-A receptor blockade during the progression of pacing-induced congestive heart failure

^a Division of Cardiothoracic Surgery, Charleston, South Carolina, USA
^* Bristol Myers Squibb Research Institute, Princeton, New Jersey, USA

View larger version (53K): [in a new window]   Figure 1 The percent change in mean arterial pressure following infusion of 10 µg of endothelin-1 (ET-1). Administration of 12.5 mg/kg b.i.d. of the ETA receptor antagonist BMS-193884 reduced the ET-1 pressor response by approximately 50%. Administration of the ETA receptor antagonist at 50 mg/kg b.i.d. virtually eliminated the ET-1 pressor response. These two doses of the ETA receptor antagonist were then used to study the effects of ETA receptor blockade with the development of pacing-induced CHF.